• Publications
  • Influence
Higher 25‐hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis
A protective association between higher vitamin D levels and the onset of multiple sclerosis (MS) has been demonstrated; however, its role in modulating MS clinical course has been little studied. WeExpand
  • 400
  • 13
Disability progression in multiple sclerosis is slower than previously reported
Objective: To investigate disease progression and risk factors in a large geographically based population with multiple sclerosis (MS), using two different inception points—clinical onset and date ofExpand
  • 293
  • 12
Monthly Ambient Sunlight, Infections and Relapse Rates in Multiple Sclerosis
Background: Monthly variation in multiple sclerosis (MS) relapses has been found. The relationship between seasonal environmental factors, infections, serum vitamin D [25(OH)D] and MS relapses isExpand
  • 135
  • 10
The natural history of primary progressive multiple sclerosis
Background: Primary progressive multiple sclerosis (PPMS) carries the worst prognosis of the multiple sclerosis (MS) subtypes and is currently untreatable. A previous analysis of the British ColumbiaExpand
  • 150
  • 8
The natural history of secondary progressive multiple sclerosis
Background The onset of secondary progression is a pivotal event in the course of relapsing–remitting (RR) multiple sclerosis (MS). Patients with secondary progressive MS (SPMS) experience continuousExpand
  • 214
  • 8
  • PDF
Relative mortality and survival in multiple sclerosis: findings from British Columbia, Canada
Objective To examine mortality and factors associated with survival in a population based multiple sclerosis (MS) cohort. Methods Clinical and demographic data of MS patients registered with theExpand
  • 102
  • 8
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model
Objectives In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were notExpand
  • 45
  • 8
  • PDF
New perspectives in the natural history of multiple sclerosis
Multiple sclerosis (MS) has entered an era of immunomodulatory drug treatment, the impact of which on long-term disease progression remains controversial. The increasing use of these therapies hasExpand
  • 205
  • 6
  • PDF
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
CONTEXT Interferon beta is widely prescribed to treat multiple sclerosis (MS); however, its relationship with disability progression has yet to be established. OBJECTIVE To investigate theExpand
  • 236
  • 5
  • PDF
The prevalence of MS in the United States
Objective To generate a national multiple sclerosis (MS) prevalence estimate for the United States by applying a validated algorithm to multiple administrative health claims (AHC) datasets. Methods AExpand
  • 164
  • 5